肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2020 BCSH指南：毛细胞白血病及变异型毛细胞白血病的诊断和治疗（修订版）

2020-12-23 英国血液学标准委员会 Br J Haematol . 2020 Dec 23.

毛细胞白血病

英国血液学标准委员会(BCSH)首次发布毛细胞白血病和变异型毛细胞白血病诊断和管理指南是在2000年，本文是对该指南的更新，涉及领域包括诊断，治疗以及治疗应答评估。

中文标题：

2020 BCSH指南：毛细胞白血病及变异型毛细胞白血病的诊断和治疗（修订版）

英文标题：

The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant

发布机构：

英国血液学标准委员会

发布日期：

2020-12-23

简要介绍：

英国血液学标准委员会(BCSH)首次发布毛细胞白血病和变异型毛细胞白血病诊断和管理指南是在2000年，本文是对该指南的更新，涉及领域包括诊断，治疗以及治疗应答评估。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 BCSH指南：毛细胞白血病及变异型毛细胞白血病的诊断和治疗（修订版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=7a7a81c0020366f2, title=2020 BCSH指南：毛细胞白血病及变异型毛细胞白血病的诊断和治疗（修订版）, enTitle=The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant, guiderFrom=Br J Haematol . 2020 Dec 23., authorId=0, author=, summary=英国血液学标准委员会(BCSH)首次发布毛细胞白血病和变异型毛细胞白血病诊断和管理指南是在2000年，本文是对该指南的更新，涉及领域包括诊断，治疗以及治疗应答评估。, cover=https://img.medsci.cn/2021111/1610378465384_2020535.jpg, journalId=0, articlesId=null, associationId=27, associationName=英国血液学标准委员会, associationIntro=英国血液学标准委员会（BCSH）是英国血液病学会（BCH, British Society for Haematology）分委员会。英国血液学标准委员会基于血液系统疾病及输血的治疗、诊断制定可循证指南。BCSH针对四个主要的临床领域有相对应的特别工作组：一般血液学，止血和血栓形成，血液肿瘤及输血。BCSH的第五个特别工作组是实验及临床实践委员会，该委员会提供其他分支未涉及的血液学临床实践及实验方面的指导。所有的BCSH指南均来自英国血液病学者及专家的临床实践。, copyright=0, guiderPublishedTime=Wed Dec 23 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>英国血液学标准委员会(BCSH)首次发布毛细胞白血病和变异型毛细胞白血病诊断和管理指南是在2000年，本文是对该指南的更新，涉及领域包括诊断，治疗以及治疗应答评估。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=28720, tagName=毛细胞白血病)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=28720, guiderKeyword=毛细胞白血病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12906, appHits=183, showAppHits=0, pcHits=1000, showPcHits=12723, likes=3, shares=25, comments=24, approvalStatus=1, publishedTime=Tue Jan 12 19:40:43 CST 2021, publishedTimeString=2020-12-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Jan 11 23:21:09 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 05:47:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 BCSH指南：毛细胞白血病及变异型毛细胞白血病的诊断和治疗（修订版）.pdf)])
2020 BCSH指南：毛细胞白血病及变异型毛细胞白血病的诊断和治疗（修订版）.pdf
下载请点击：
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1195547, encodeId=47ca119554e33, content=真不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=14895527730, createdName=ms5000000692672910, createdTime=Mon Feb 21 08:23:46 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061081, encodeId=37e0106108179, content=新的认识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Sat Oct 16 18:11:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056545, encodeId=5949105654506, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:32 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970375, encodeId=0f809e037527, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ed5511789, createdName=最后一直多巴胺, createdTime=Wed Jun 02 16:30:29 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967365, encodeId=989796e365f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:31:45 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2022-02-21 ms5000000692672910

    真不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1195547, encodeId=47ca119554e33, content=真不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=14895527730, createdName=ms5000000692672910, createdTime=Mon Feb 21 08:23:46 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061081, encodeId=37e0106108179, content=新的认识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Sat Oct 16 18:11:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056545, encodeId=5949105654506, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:32 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970375, encodeId=0f809e037527, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ed5511789, createdName=最后一直多巴胺, createdTime=Wed Jun 02 16:30:29 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967365, encodeId=989796e365f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:31:45 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-10-16 ms6844877495285940

    新的认识

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1195547, encodeId=47ca119554e33, content=真不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=14895527730, createdName=ms5000000692672910, createdTime=Mon Feb 21 08:23:46 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061081, encodeId=37e0106108179, content=新的认识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Sat Oct 16 18:11:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056545, encodeId=5949105654506, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:32 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970375, encodeId=0f809e037527, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ed5511789, createdName=最后一直多巴胺, createdTime=Wed Jun 02 16:30:29 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967365, encodeId=989796e365f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:31:45 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-09-30 13f0c37dm61暂无昵称

    值得学习。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1195547, encodeId=47ca119554e33, content=真不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=14895527730, createdName=ms5000000692672910, createdTime=Mon Feb 21 08:23:46 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061081, encodeId=37e0106108179, content=新的认识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Sat Oct 16 18:11:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056545, encodeId=5949105654506, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:32 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970375, encodeId=0f809e037527, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ed5511789, createdName=最后一直多巴胺, createdTime=Wed Jun 02 16:30:29 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967365, encodeId=989796e365f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:31:45 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-06-02 最后一直多巴胺

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1195547, encodeId=47ca119554e33, content=真不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=14895527730, createdName=ms5000000692672910, createdTime=Mon Feb 21 08:23:46 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061081, encodeId=37e0106108179, content=新的认识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Sat Oct 16 18:11:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056545, encodeId=5949105654506, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:32 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970375, encodeId=0f809e037527, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ed5511789, createdName=最后一直多巴胺, createdTime=Wed Jun 02 16:30:29 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967365, encodeId=989796e365f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:31:45 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
    2021-05-21 tyiutyu16

    学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2020 BSH指南：毛细胞白血病(HCL)和变异型毛细胞白血病 (HCL-V)的诊断和管理

英国血液病学学会(BSH,British Society for Haematology) · 2020-10-14

2015 ESMO临床实践指南：毛细胞白血病的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2015-08-12

拓展阅读

2015 ESMO临床实践指南：毛细胞白血病的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2015-08-12

2020 BSH指南：毛细胞白血病(HCL)和变异型毛细胞白血病 (HCL-V)的诊断和管理

英国血液病学学会(BSH,British Society for Haematology) · 2020-10-14

2022 国家专家组共识意见：毛细胞白血病的可测量残留病变

国外血液科相关专家小组 · 2022-12-13